advertisement
Abstract #46116 Published in IGR 13-2
Ocular hypotensive effect, preservation of visual fields, and safety of adding dorzolamide to prostaglandin therapy for twelve months
Inoue K; Masumoto M; Wakakura M; Tomita GClinical Ophthalmology 2011; 5: 393-396
Purpose: To prospectively evaluate the safety, hypotensive effect, and preservation of visual fields of dorzolamide when added to latanoprost. Subjects and methods: This study included 46 patients (46 eyes) with primary open-angle glaucoma who had been treated with latanoprost. Dorzolamide (1%) was added to latanoprost, and the intraocular pressure (IOP) was monitored before and after 3, 6, and 12 months. The mean deviation shown by Humphrey perimetry was compared before and after twelve months of treatment. Adverse reactions were monitored over the 12-month study period. Results: The mean baseline IOP was 17.2 (plus or minus) 3.0 mmHg while those after 3, 6 and 12 months of treatment were 14.9 (plus or minus) 3.0 mmHg, 14.5 (plus or minus) 3.2 mmHg, and 14.6 (plus or minus) 2.6 mmHg respectively (P < 0.0001, 1-(beta)(power) = 0.9999571). The absolute reduction of IOP and the percent reduction were similar after 3, 6, and 12 months of treatment. The mean deviation on Humphrey perimetry was similar before and after twelve months of treatment. Three patients discontinued dorzolamide therapy due to elevation of IOP and one patient discontinued it because of adverse reactions. Conclusion: Dorzolamide is safe and effective when used for twelve months as add-on therapy to latanoprost for open-angle glaucoma.
K. Inoue. Inouye Eye Hospital, Tokyo, Japan. Email: inoue-k@fd5.so-net.ne.jp
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)
